| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the presentation of two abstracts at ObesityWeek 2025 taking place November 4-7, 2025, in Atlanta, Georgia.
Poster presentation name: Enobosarm Reduced Body Weight and Fat Regain and Preserved Lean Mass After Discontinuing Semaglutide
Presenter: Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana
Session Date: Tuesday, November 4, 2025
Session Time: 7:30 pm - 8:30 pm Eastern Time
Session Room: Exhibit Hall A1
Oral presentation name: Enobosarm in Combination With GLP-1RA is Selective for Fat Loss While Preserving Lean and Function
Presenter: Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru
Session Date: Friday, November 7, 2025
Session Time: 8:00 am - 8:15 am Eastern Time
Session Room: GWCC Building A: A411-A412
Posted In: VERU
